Список литературы

  1. Комаров Ф.И., Коровкин Б.Ф./ Биохимические показатели в клинике внутренних болезней/ Москва, МЕДпресс, 2000, с.158-160.
  2. С.С. Бессмельце, К.М. Аблулкадыров/ Бисфосфонаты в лечении больных множественной миеломой// Проблемы гематологии, 2001, 3; с.23-32.
  3. S.M. Ali, F.J. Esteva, G. Hortobagyi, K. Henick et al/ Safety of longterm of bisphosphonates in cancer patients// АSCO 1998, p.168.
  4. L.J.M.Y. Blomer/ History of bisphosphonates: Discovery and History of the nonmedialuses of bisphosphonates// pp.111-124.
  5. L. Costa, R. Coleman, E. Curley, A. Qeintela et al/ Dose intense therapy of bone metastases with pamidronate// АSСО 1998, p.216.
  6. C.A. Crohns, M. Untch, G. Konecty/ Different bisphosphonates have direct cytotoxic effect on three breast cancer cell lines and breast cancer tumor tussue// ASCO 2001, 2005.
  7. L. Costa, L. Demers, A. Oliveira, J. Schaller et al/ Dose intense therapy of bone metastases with pamidronate// ASCO 2001, p.1711.
  8. F.P. Coxon, M.H. Helfrich, R.G. Van’tHolf et al/ Protein gepanylgeranylation in required for osteoclast inhibition by bisphosphonates and GGTI-298// J.Bone Min.Res., Aug., 15[8], pp.146-76.
  9. D.F. Huhes, B.R. Mclinand, R.G. Russell, M. Gowen/ Inhibition of osteoclast-lake cell formation by bisphosphonates in long-term cultures of human bone marrow// J.Clin.Invest., 1989, 83, pp.1930-1935.
  10. I.J. Diel, M.R. Lichiniser, J.J. Body, K. Schlosser et al/ Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate// ECCO 10/99/269.
  11. I.J. Diel, E.F. Solomayer, S.D. Costa et al/ Reduction in new metastases in breast cancer with adjuvant clodronate treatment// N.Engl.J.Med, 1998, 339, pp.357-363.
  12. J.E. Dunford, K. Thompson, F.P. Coxon et al/ Structure-activity relationships for inhibition of farnesyl diphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates// J.Pharm.Exp.Ther., 2001, Feb., p.296.
  13. T. Erem, M. Kos, P. Polat, M. Yildirim et al/ The comparison of radiotherapy and radiotherapy plus pamidronate on pain palliation of metastatic bone disease// ECCO 90/99, pp.1489.
  14. Н. Fleischl/ Biрhosphonatеs in bone disease// Асadеmic Press 2000, pp.88-110.
  15. J.R. Green, K. Muller, K.A. Jaeggi/ Preclinical pharmacology of CGP 42’446, a new potet heterocyclic bisphosphonate compound// J.Bone Miner. Reg., 1994, 9, pp.745-751.
  16. G.N. Hortobady, R.L. Theriault, L. Porter, D. Blayney/ Efficacy of pamidronate in reducing skeletal complication in patients with breast cancer and lytic bone metastases// N.Engl.J.Med, 1996, 335, pp.1785-1791.
  17. G.N. Hortobagy, R.L. Theriault, A. Lipton/ Lond-term prevention of skeletai complication of metastatic breast cancer with hamidronate// J.Clin.Oncol., 1998, 16, pp.2038-44.
  18. R. Haltborn, R. Gundesen, S.Ryden/ Effecacy pamidronate in breast cancer with bone metastases: A randomised, double-blind placebo-controlled multicenter study// Anticancer Rec, 1999, 19, pp.3383-92.
  19. J.A. Kanis, T. Powles, A.H.G. Paterson/ Clodronate decreases the frequency of skeletal metastases in wотеп with breast cancer// Bone, 1996, 19, pp.663-667.
  20. A. Lipton, G. Hortobagyi, J. Simeone, R. Knight/ Progression of bone metastases in breast cancer patients receiving pamidronate// АSCO 1998/469.
  21. J.T. Mundy, T.J. Martin/ Physiology and pharmacology of bone handbook of experimental pharmacology, V.107, p.165.
  22. P. Major, A. Lortholary, J. Hon et al/ Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials// J.Clin.Oncol 2001, 19[2], pp.558-67.
  23. M. Pecherstorfer, B. Hammerl, R. Jilch et al/ Effects of bisphosphonates pamindronate, clodronate and ibandronate on CD 69, an early T-lymphocyte activation marker// ASCO 1998, p.1719.
  24. R.G.G. Russel, M.J. Rogers, J.C. Fritn, S.P. Luckman et al/ The pharmacology of bisphosphonates and new insights into their mechanisms of action// J.Bone Miner., Rec 1999, 14, Suppl, pp.53-65.
  25. M. Pecherstorfer, E. Steinhauer, S.D. Pawsey/ Ibandronic acid is more effective than pamidronate in lowering serum calcium in patients with severe hypercalcemia of malignancy, and has at least equal efficacy to pamindronate in HCM patients with lower baseline calcium levels. Results of a randomised, open label, comparative study// ASCO 2001, p.1535.
  26. T.J. Powles, A.G.H. Paterson, S. Nevantaus, M. Legault/ Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer// Prod.Proc.An.Soc.Clin.Oncol., 1998, 17, 123a.
  27. M.J. Rogers, R.G.G. Russell, G.M. Blackbern, M.P. Willianson et al/ Incorporation of bisphosphonates into adenine nucleotides by amoebe of the cellular slime mould// Dictyostelium discoideum. Biochem J, 1994, 303-11.
  28. M.J. Rogers, R.G. Brown, V. Hodkin, G.M. Blackburn et al/ Bisphosphonates are incorporated into adenine nucleotides by human aminoacyd-tRNA syntetase enzymes// Biochem.Biophys.Res.Commun., 1996, 224, 863-9.
  29. L.S. Rosen, D. Gordon, J.W. Dugan et al/ Zoledronic acid [4 mg] is more effective than pamidronate [90mg] for treatment bone metastases cancer patients with at least one osteolytic lesion, presented at the 27th Eur.Soc.for Med.Oncol.Congress, Oct., 18-22, 2002.
  30. A.H.G. Paterson, T.J. Powles, J.A. Kanis, E. McClowskey et al/ Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer// J.Clin.Oncol., 1993, 11, pp.59-65.
  31. G.L. Plosker, K.L. Goa/ Clodronate. Review of its pharmacolodical properties and therapeutic efficacy in resorptive bone disease// Drags, 1994, 47, pp.945-952.
  32. M. Sato, W. Grasser/ Effects of bisphosphonates of isolated rat osteoclasts as examined by refracted light microscopy// J. Bone Min. Rec., 1990, 5, pp.31-40.
  33. T. Saarto, C. Blomquist, P. Virkkunen/ Adjuvant clodronate treatment doses not reduce the frequency of skeletal metastases in node-poitive breast cancer patients: 5 years results of a randomized controlled trial// J.Clin.Oncol., 2001, 19, pp.10-17.
  34. R.A. Saber, T.Z. Mahran, M.S. Zaghloul, K.M. Abo-Elinin/ Response of skeletal metastases to systemic chemotherapy in patients with breast cancer// ASCO 2001, 2011.
  35. M.J. Seibel, S.P. Robins, J.P. Belizikian/ Dynamics of bone and cartilage metabolism// San Diego, London, Academic Press, pp.261-273.
  36. L.S. Rosen, D. Gordon, B.S. Antonio et al/ Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lisions of multiple myeloma: a phase III, double-blind, comparative trial// Cancer J., 2001, 7(5), pp.377-387.
  37. Т. Таibе, I. Еlотаа, С. Вlотqvist, M.N.C. Beneton еt аl/ Histomorphemetrie evidence for osteoclasts-mediated bone resorption in metastases breast cancer// Еur J. Cancer, 1993, 23А, 1, pp.677-1681.
  38. R.L. Theriaul, A. Lipton, G.H. Hortobagyiet al/ Pamidronate reduces skeletal morbodoty in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial// J. Clin. Oncol., 1999, 17, pp.846-854.
  39. J.M. Zmuda, J.A. Cauley, B. Ljung et al/ Bone mineral density and risk of breast cancer among older women: differences by stage at diagnosis// ASCO 2001, p.1656.
  40. Harrison’s principles of internal Medicine// 14th edition, pp.2685-2743.
  41. Woitge H.W. et al/ Novel serum markers of bone resorption: clinical assessment and comparison with establisbed urinary indices// J.Bone a Miner. Res., 1999, 14, pp.792-801.
  42. I.J. Diel/ Antitumor effects of bisphosphonates// Drugs, 2000, v.59, pp.391-399.
  43. J.A. Kanis, N. O`Rourke, E. McClaskey/ Consequences of neuplasia induced resorption and the use of clodronate// Int.J.Oncol., 1994, v5, pp.713-731.
  44. Z. Tomasevic, S. Jelic, I. Popov et al/ Tumor "flare" hypercalcemia: One more indication for bisphosphonates usage?// Ann.of Oncol, 2000, v.11, suppl.4, p.39, abstr.166.
  45. J.A. Kanis, T. Powles, A.H.G. Paterson et al/ Consequeces of neoplasia-induced bone resorption and the use of clodronate// Int.J.of Oncol., 1994, v5, pp.713-731.
  46. М.Р. Личиницер, Н.Н. Семенов, А.А. Мещеряков с соавт./ Клиническая эффективность бондроната при метастазах в кости рака молочной железы// Вестн.РОНЦ, 2002, 3, с.20-25.
  47. G. Francini, M. Montagnani, R. Petrioli/ Comparison between CEA,TRA,CA 15/3 and hydroxyproline, alkaline phosphatase in the follow-up of bone metastases in breast cancer// Int.J.Biol.Markers, 1990, v.5(2), pp.62-72.
  48. S. Gnudi, L. Lisi, N. Malavatova/ Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women// Int.J.Tissue react, 2001, v.23, pp.33-37.
  49. J.C. Souberbielle, C. Cormier, C. Kindermans/ Bone markers in clinical practice// Cur.Opin.Rheum, 1999, v.11, pp.312-319.
  50. J.R. Berenson, L.S. Rosen, A. Howell et al/ Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study// Cancer, 2001, 91(7), pp.191-200.
  51. J.J. Vinholes, C-Y. Guo, O.P. Purohit et al/ Metobolic effects of pamidronate in patients with metastatic bone disease// Brit.J.Cancer, 1996, v.73, pp.1089-1095.
  52. R.E. Coleman, P. Smith, R.D. Rubens/ Clinical course and prognostic factors following bone recurrence from breast cancer// Brit.J.Cancer, 1998, v.77(2), pp.336-340.
  53. Conte H., Latreillo J., Mauriac L. et al/ Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group// J.Clin.Oncol, 1996, 14(9), pp.2552-2559.
  54. Возный Э.К., Добровольская Н.Ю., Большакова С.А./ Специальные клинические ситуации: метастазы в легкие, плевру, печень, головной мозг// Практ.онкол., 2000, 2, с.38-40.
  55. Bilimoria M., Assikis V., Jordan V./ Should adjuvant tamoxifen treatment be stopped at 5 years?// Cancer J. Sci.Am., 1996, 2, pp.140-150.
  56. Love R., Mazess R., Barden H. et al/ Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer// Ann. Of Inter. Med., 1991, 115, pp.860-864.
  57. Harper-Wynne C., Ross G., Sacks N. et al/ Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer patient// Cancer Epid.Biomark.Prev., 2002, 11(7), pp.614-621.
  58. Love R., Mazess R., Barden H. et al/ Effects of tamoxifen in bone miniral density in postmenopausal women with breast cancer// N.Engl.J.Med, 1992, 326, pp.852-856.
  59. Zilembo N., Baietta E., Martinetti A. et al/ Markers of bone turnover in metastatic breast cancer patient having progressed on tamoxifen: short term effect of further treatment with either exemestane or megestrol acetate// Eur.J.cancer, 2001, 37(16), p.193.
  60. Heshmati H., Khosla S., Robins S. et al/ Role of low levels of endogenius estrogen in regulation of bone resorption in late postmenopausal women// J.Bone Miner.Res., 2002, 17(1), pp.172-178.
  61. Harper-Wynne C., Ross G., Sacks N., Dowsett M./ A pilot prevention study of the aromatase inhibitor letrosole: effects on breast cancer cell proliferation and bone/lipid indices in healthy postmenopausel women// Breast Cancer Res. Treat., 2001, 69, 225, abstr.136.
  62. Eastell R., Adams J./ Results of the "Arimidex" (anastrozole) tamoxifen alone or in combination trial: effects on bone mineral density and bone turnover// Ann.of Oncol., 2002, 13(5), 32.
  63. Тинсли Р. Харрисон/ Внутренние болезни// 2т., М., Практика-Мак-Гроу-Хилл, 2002.
  64. Barri Y.M., Knochel J.P./ Hypercalcemia and electrolyte disturbances in malignancy hematology// Oncology Clin.of North Amer., 1996, 10(4), pp.775-790.
  65. Ralston S.H., Thierbaud D., Herrmann Z. et al/ Dose-response study of ibandronate in the tretment of cancer-associated hypercalciemia// Brit. J. of Cancer, 1997, 75(2), pp.295-300.
  66. Harnick J.I.J., Papapoulos S.E., Blanksma H.J. et al/ Paget`s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate// Br. Med.J, 1987, 295, pp.1301-1305.
  67. Pecherstorfer M., Jilch R., Santy A. et al/ Effect of treatment with aminobisphosphonates pamidronate and ibandronate in circulating lymphocyte subpopulations// J. Bone Min. Res., 2000, 15(1), pp.147-154.
  68. Моисеенко В.М., Блинов Н.Н./ Современная тактика лечения больных злокачественнми новообразованиями с метастазами в кости// С-Пб.: 1996, с.31.

Согласен Данный веб-сайт содержит информацию для специалистов в области медицины. В соответствии с действующим законодательством доступ к такой информации может быть предоставлен только медицинским и фармацевтическим работникам. Нажимая «Согласен», вы подтверждаете, что являетесь медицинским или фармацевтическим работником и берете на себя ответственность за последствия, вызванные возможным нарушением указанного ограничения. Информация на данном сайте не должна использоваться пациентами для самостоятельной диагностики и лечения и не может быть заменой очной консультации врача.

Сайт использует файлы cookies для более комфортной работы пользователя. Продолжая просмотр страниц сайта, вы соглашаетесь с использованием файлов cookies, а также с обработкой ваших персональных данных в соответствии с Политикой конфиденциальности.